SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in reducing HCW susceptibility to SARS-CoV-2, howev...

Full description

Bibliographic Details
Main Authors:	Kevin D. Dieckhaus, Min-Jung Kim, Jian-Bing Shen, Tina S. Liang, Michael J. Kleinberg, Kristen M. Siedlarz, David B. Banach, Mark L. Metersky, Rob P. Fuller, Eric M. Mortensen, Bruce T. Liang
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Vaccines
Subjects:	SARS-CoV-2 COVID-19 neutralizing antibody bnt162b2 mRNA-1273 healthcare workers
Online Access:	https://www.mdpi.com/2076-393X/11/2/358

Similar Items

Risk of herpes zoster following mRNA COVID-19 vaccine administration
by: Ana Florea, et al.
Published: (2023-12-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
by: Anna Kaznadzey, et al.
Published: (2022-04-01)

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
by: Daniele Focosi, et al.
Published: (2022-11-01)

Is a single COVID-19 vaccine dose enough in convalescents ?
by: Daniele Focosi, et al.
Published: (2021-09-01)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
by: Farah M. Shurrab, et al.
Published: (2022-01-01)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
by: Miriam Echaide, et al.
Published: (2023-03-01)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
by: Chiranjib Chakraborty, et al.
Published: (2021-07-01)

A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection
by: Zaeema Naveed, et al.
Published: (2024-03-01)

Peripheral Nervous System Adverse Events after the Administration of mRNA Vaccines: A Systematic Review and Meta-Analysis of Large-Scale Studies
by: Yu-Hsin Lai, et al.
Published: (2022-12-01)

Tozinameran (Pfizer, BioNTech) and Elasomeran (Moderna) Efficacy in COVID-19—A Systematic Review of Randomised Controlled Trial Studies
by: Piotr Ratajczak, et al.
Published: (2023-05-01)

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
by: Soledad González, et al.
Published: (2022-09-01)

The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines
by: Monika Skorupa, et al.
Published: (2022-03-01)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
by: Khalid Hajissa, et al.
Published: (2021-08-01)

Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
by: Daniele Focosi, et al.
Published: (2022-01-01)

SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review
by: Caterina Ledda, et al.
Published: (2022-01-01)

Durability of Protection Post–Primary COVID-19 Vaccination in the United States
by: Amanda Zheutlin, et al.
Published: (2022-09-01)

COVID-19 mRNA BNT162b2 vaccine safety and antibodies level among healthcare workers at Centre Hospitalier du Nord
by: Rosabelle Chedid, et al.
Published: (2022-04-01)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
by: Nigam H. Padhiar, et al.
Published: (2022-05-01)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
by: Cynthia M. Rohde, et al.
Published: (2023-02-01)

From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community
by: Melinda C. Joyce, et al.
Published: (2022-12-01)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
by: Catherine E. Raptis, et al.
Published: (2022-10-01)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
by: Hao Zhou, et al.
Published: (2021-08-01)

IMUNOGENICIDADE DE UM PRIMEIRO REFORÇO COM BNT162B2 OU MRNA-1273 DE DOSE COMPLETA: UM ESTUDO RANDOMIZADO EM ADULTOS ≥75 ANOS (EU-COVAT-1) DO CONSÓRCIO VACCELERATE
by: Jon Salmanton-Garcia, et al.
Published: (2023-10-01)

SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine
by: Wan Muhammad Azfar Wan Shuaib, et al.
Published: (2023-12-01)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
by: Luigia Trabace, et al.
Published: (2022-04-01)

Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
by: Tiziana Grassi, et al.
Published: (2022-11-01)

Safety and efficacy of RNA vaccines: State of the art
by: A. V. Blagov, et al.
Published: (2021-11-01)

Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals
by: Susan L. Uprichard, et al.
Published: (2022-02-01)

Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
by: Xuan Wang, et al.
Published: (2023-09-01)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022-11-01)

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
by: Ilaria Vicenti, et al.
Published: (2021-11-01)

Association between sleep duration and antibody acquisition after mRNA vaccination against SARS-CoV-2
by: Muneto Izuhara, et al.
Published: (2023-12-01)

Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers
by: Niki Vassilaki, et al.
Published: (2021-08-01)

COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated
by: Anke Hüls, et al.
Published: (2022-03-01)

Influence of the Single Nucleotide Polymorphisms rs12252 and rs34481144 in <i>IFITM3</i> on the Antibody Response after Vaccination against COVID-19
by: Ieva Čiučiulkaitė, et al.
Published: (2023-07-01)

Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan
by: Yu Nishida, et al.
Published: (2021-12-01)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
by: Passakorn Wanchaijiraboon, et al.
Published: (2023-02-01)

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review
by: SeyedAhmad SeyedAlinaghi, et al.
Published: (2022-05-01)